Literature DB >> 21083656

Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients.

Soley Bayraktar1, Ulas D Bayraktar, Alexandra Stefanovic, Izidore S Lossos.   

Abstract

Extranodal marginal zone B-cell lymphoma is the most common orbital tumour. We conducted a retrospective analysis to examine: (i) the impact of initial presentation and staging on outcome and (ii) response to various treatment modalities and the effect of the latter on recurrence. Ninety patients with primary ocular adnexal marginal zone lymphoma (POAML) diagnosed at our institution between 1984 and 2009 were studied. POAML was associated with monoclonal gammopathy (13%) at presentation. Most POAML patients (86%) presented with Ann-Arbor stage I disease. Radiotherapy led to excellent local control, but relapses occurred in 18% of Ann-Arbor stage I patients during a median follow-up of 5 years. Local relapses, including secondary central nervous system (CNS) involvement, were observed in patients receiving radiation doses <30·6 Gy. No differences in relapse rate and survival were observed between patients who did or did not undergo staging bone marrow biopsy. Ann-Arbor stage II-IV disease and high lactate dehydrogenase levels were associated with shorter freedom from progression. In conclusion, POAML is an indolent lymphoma with continuous risk for relapse. Radiation doses of at least 30·6 Gy should be given in Ann-Arbor stage I disease, since lower doses may be more frequently associated with relapses, including CNS relapses.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21083656      PMCID: PMC3076069          DOI: 10.1111/j.1365-2141.2010.08429.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  61 in total

1.  Lymphoma of the ocular adnexa: A study of 353 cases.

Authors:  Judith A Ferry; Claire Y Fung; Lawrence Zukerberg; Mark J Lucarelli; Robert P Hasserjian; Frederic I Preffer; Nancy L Harris
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  Imaging features of ocular adnexal lymphoproliferative disease.

Authors:  T J Sullivan; A A Valenzuela
Journal:  Eye (Lond)       Date:  2006-10       Impact factor: 3.775

3.  Prognostic significance of anatomic subsites: results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma.

Authors:  Heerim Nam; Yong Chan Ahn; Yoon-Duck Kim; Younghyeh Ko; Won Seog Kim
Journal:  Radiother Oncol       Date:  2008-10-22       Impact factor: 6.280

Review 4.  Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy.

Authors:  A J M Ferreri; R Dolcetti; M-Q Du; C Doglioni; A Giordano Resti; L S Politi; C De Conciliis; J Radford; F Bertoni; E Zucca; F Cavalli; M Ponzoni
Journal:  Ann Oncol       Date:  2007-11-06       Impact factor: 32.976

5.  More than a third of non-gastric malt lymphomas are disseminated at diagnosis: a single center survey.

Authors:  Mirjana Sretenovic; Milica Colovic; Gradimir Jankovic; Nada Suvajdzic; Biljana Mihaljevic; Natasa Colovic; Milena Todorovic; Henry Dushan E Atkinson
Journal:  Eur J Haematol       Date:  2009-01-09       Impact factor: 2.997

6.  Ocular adnexal mucosa-associated lymphoid tissue lymphoma with polyclonal hypergammaglobulinemia.

Authors:  Toshinobu Kubota; Suzuko Moritani; Tadashi Yoshino; Hirokazu Nagai; Hiroko Terasaki
Journal:  Am J Ophthalmol       Date:  2008-03-12       Impact factor: 5.258

7.  Primary ocular adnexal MALT lymphoma: a long-term follow-up study of 114 patients.

Authors:  Kazuki Tanimoto; Akihiro Kaneko; Shigenobu Suzuki; Naohiro Sekiguchi; Takashi Watanabe; Yukio Kobayashi; Yoshikazu Kagami; Akiko Miyagi Maeshima; Yoshihiro Matsuno; Kensei Tobinai
Journal:  Jpn J Clin Oncol       Date:  2007-06-11       Impact factor: 3.019

8.  Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma.

Authors:  E-K Song; S-Y Kim; T M Kim; K-W Lee; T Yun; I-I Na; H Shin; S H Lee; D W Kim; S I Khwarg; D S Heo
Journal:  Ann Oncol       Date:  2007-10-17       Impact factor: 32.976

9.  Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

Authors:  B Esmaeli; P McLaughlin; B Pro; F Samaniego; I Gayed; F Hagemeister; J Romaguera; F Cabanillas; S S Neelapu; R Banay; L Fayad; M Wayne Saville; L W Kwak
Journal:  Ann Oncol       Date:  2009-01-15       Impact factor: 32.976

10.  High incidence of autoimmune disease in Japanese patients with ocular adnexal reactive lymphoid hyperplasia.

Authors:  Toshinobu Kubota; Suzuko Moritani
Journal:  Am J Ophthalmol       Date:  2007-07       Impact factor: 5.258

View more
  16 in total

1.  Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.

Authors:  Macarena I de la Fuente; Aya Haggiagi; Adrienne Moul; Robert J Young; Charif Sidani; Arnold Markoe; Francisco Vega; Lisa M DeAngelis; Izidore S Lossos
Journal:  Leuk Lymphoma       Date:  2016-09-21

2.  Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China.

Authors:  Hui Yu; Yu-Xin Du; Zhen-Chang Sun; Xiao-Rui Fu; Nan Tan; Wei-Feng Gong; Ming-Zhi Zhang
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

Review 3.  Recent developments in nongastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Marlene Troch; Barbara Kiesewetter; Markus Raderer
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

4.  The expressions of metadherin and LEF-1 in mucosa-associated lymphoid tissue lymphoma of ocular adnexal.

Authors:  Dan Qi; Hong Lin; Yan Gao; Jing Lin; Li-Ting Hu; Gui-Qiu Zhao
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

5.  Clinicopathologic Characteristics Associated with Prognosis in Ocular Extranodal Marginal Zone B Cell Lymphoma.

Authors:  Soyeon Choi; Minjung Seo; Seol Hoon Park; Jae-Cheol Jo; Seoung Wan Chae; Ju-Hyang Lee; Hee Jeong Cha
Journal:  Medicina (Kaunas)       Date:  2022-06-17       Impact factor: 2.948

Review 6.  Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives.

Authors:  Dominic Kaddu-Mulindwa; Lorenz Thurner; Konstantinos Christofyllakis; Moritz Bewarder; Igor Age Kos
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

7.  Orbital lymphoma: imaging features and differential diagnosis.

Authors:  Gema Priego; Carles Majos; Fina Climent; Amadeo Muntane
Journal:  Insights Imaging       Date:  2012-04-18

8.  Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.

Authors:  Ombretta Annibali; Francesca Chiodi; Chiara Sarlo; Magdalena Cortes; Francesco M Quaranta-Leoni; Carlo Quattrocchi; Antonella Bianchi; Stefano Bonini; Giuseppe Avvisati
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

Review 9.  Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party.

Authors:  Yong Park; Byung Bae Park; Ji Yun Jeong; Wook Youn Kim; Seongsoo Jang; Bong Kyung Shin; Dong Soon Lee; Jae Ho Han; Chan-Jeoung Park; Cheolwon Suh; Insun Kim; Hyun-Sook Chi
Journal:  Korean J Intern Med       Date:  2016-11-01       Impact factor: 2.884

10.  Extranodal Marginal Zone Lymphoma of Ocular Adnexa: Outcomes following Radiation Therapy.

Authors:  Sean Platt; Yahya Al Zahrani; Nakul Singh; Brian Hill; Sheen Cherian; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.